Clinical Trial

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

Study acronym: Navigator
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.
Protocol Amendment History 1 change
notable Trial sites expanded: 12 -> 20 locations 2026-08-08
Trial Details
NCT Number NCT07684820
Lead Sponsor Expedition Therapeutics, Inc
Conditions Chronic Obstructive Pulmonary Disease (COPD)
Enrollment 600 participants
Start Date 2026-06-30
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-07-11 (estimated)
Updated on ClinicalTrials.gov 2026-08-07